New Report "Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013" available through Aarkstore Enterprise
10/27/2009

"Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.

Online PR News – 27-October-2009 – – Comprehensive Forecasts AND Detailed Budget Benchmarks

"Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match. Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever. At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.
Table of Contents :
Chapter 1: Drug Brand Profiles

Alkylating Agents

• Paraplatin (BMS)

• Alkeran (Celgene)

• Satraplatin (Celgene)

• Treanda/SDX-105 (Cephalon)

• Perifosine/KRX-0401 (Keryx)

• UFT (Merck KGaA)

• Picoplatin (Poniard)

• Eloxatin (Sanofi-Aventis)

• Temodar (Schering-Plough)

Antimetabolites

• Dacogen (Eisai/MGI, J&J)

• Alimta (Eli Lilly)

• Gemzar (Eli Lilly)

• Clolar (Genzyme)

• Arranon/506U78 (J&J)

• Xeloda (Roche)

• S-1 (5FU – combo) (Sanofi-Aventis)

Antimitotics

• ABT-751 (Abbott)

• Abraxane (Abraxis)

• Ixempra (BMS)

• Taxol (BMS)

• Javlor (Pierre Fabre)

• Taxotere (Sanofi-Aventis)

• XRP9881 (Sanofi-Aventis)

Cytotoxic Antibiotics

• IPI-504 (AstraZeneca)

• Amrubicin/Calsed (Celgene)

• Doxil (J&J, Schering-Plough)

• RAD001 (Afinitor) (Novartis)

• Ellence/Pharmorubicin (Pfizer)

Other Classes

• ABT-510 (Abbott)

• PDX (Pralatrexate) (Allos)

• ZD4054 (AstraZeneca)

• MGCD0103 (Celgene)

• Revlimid (Celgene)

• Thalomid (Celgene)

• Vidaza (Celgene)

• Trisenox (Celgene)

• Enzastaurin (Eli Lilly)

• XL647 (Exilixis)

• Thyrogen (Genzyme)

• Elesclomol (GlaxoSmithKline)

• Hycamtin (GlaxoSmithKline)

• Ispinesib (GlaxoSmithKline)

• Marqibo (Hana Biosciences)

• MDV3100 (Medivation)

• Deforolimus (Merck)

• Zolinza (Merck)

• Azedra (Molecular Insight)

• Azixa (MPC-6827) (Myriad Genetics)

• NKTR-102 (Nektar)

• ASA404 (Novartis)

• EPO906 (Novartis)

• Camptosar (Pfizer)

• Aflibercept (Sanofi-Aventis)

• Xaliproden (Sanofi-Aventis)

• Sarasar (Schering-Plough)

• Velcade (Takeda)

• Torisel (CCI-779) (Wyeth)

Tyrosine Kinase Inhibitors

• AMG 706 (Amgen)

• Iressa (AstraZeneca)

• Recentin (AZD2171) (AstraZeneca)

• Zactima/AZD6474 (AstraZeneca)

• Nexavar (Bayer)

• BMS-354825/Sprycel (BMS)

• Tarceva (Genentech, Roche)

• Armala (Pazopanib) (GlaxoSmithKline)

• Tykerb/GW572016 (GlaxoSmithKline)

• AMN107/Tasigna (Novartis)

• Glivec/Gleevec (Novartis)

• PKC412 (Novartis)

• Axitinib (Pfizer)

• CP-751871 (Pfizer)

• Sutent (Pfizer)

• Alvocidib (Sanofi-Aventis)

• Bosutinib (Wyeth)

• HKI-272 (Wyeth)

Chapter 2: Market Outlooks by Indication

• Breast Cancer

• Colorectal Cancer

• Leukemia

• Lung Cancer

• Prostate Cancer

Chapter 3: Oncology Drug Manufacturer Profiles

• Amgen

• AstraZeneca

• Bristol-Myers Squibb

• Celgene

• Eli Lilly

• GlaxoSmithKline

• Johnson & Johnson

• Merck

• Novartis

• Pfizer

• Roche and Genentech

• Sanofi-Aventis

• Schering-Plough

Chapter 4: Brand Spending Benchmarks

How much do teams spend to commercialize and launch their oncology drugs?
This real-world benchmarking data tabulates market-focused budgets from the lab bench to the pharmacy shelf.Track average brand spending by market entrance, indication

approvals and peak sales levels for the following areas:

Spending by Budget Category

• Advertising and Promotion
• Decision Support
• Medical Affairs
• Market Access

Spending by Time Period

• Pre-Clinical to Phase 2
• Phase 3a
• Phase 3b
• First Year on the Market

For more information, please visit :
http://www.aarkstore.com/reports/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013-8078.html
Or email us at press@aarkstore.com or call +919272852585

visit our website